Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MDT stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.

Medtronic Stock Declines 5.6% in a Month: Time to Buy the Dip?

Zimmer Biomet Hlds

Robotic surgery used to be fodder for science fiction movies. Not anymore.

2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead

AbbVie

Archer-Daniels-Midland Company

Albemarle

Amcor Plc

Air Products and Chemicals

Atmos Energy

Franklin Resources

C.H. Robinson Worldwide

Chevron

Con Ed

Federal Realty Investment Trust

Hormel Foods

Johnson & Johnson

Coca-Cola

Kenvue

NextEra Energy

Realty Income Corp

PepsiCo

J. M. Smucker

Stanley Black & Decker

T. Rowe Price Group

Exxon Mobil

Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends

Merck

Investors looking for stocks to hold on to for a while might want to consider dividend-paying companies. Besides offering a regular stream of passive income, dividend stocks have generally outperformed their non-dividend peers over the long run.

2 Healthcare Dividend Stocks to Hold for the Long Haul

GALWAY, Ireland , Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024.

Medtronic announces cash dividend for third quarter of fiscal year 2025

Genuine Parts

Target

Dividend Aristocrats are an attractive group of stocks for dividend growth investors because of their blue chip quality and proven track record. The stocks pay reliable dividends and grow their distributions annually, helping to compound returns and offset inflation.

5 Dividend Aristocrats to Buy Now and Hold Through 2025

Medtronic remains a buy due to its attractive valuation and steady EPS growth, despite recent sector-wide selling pressure and modest losses. Q2 results beat Wall Street expectations, with revenue up 5% year-over-year, and management raised FY 2025 revenue and earnings estimates. Key risks include supply chain issues, competition, policy changes, and currency fluctuations, but MDT's free cash flow yield and technical support levels are strong.

Medtronic: Guidance Raised, Solid Dividend, Shares Still A Bargain

Apple

McDonald's

Microsoft

Procter & Gamble

Charles Schwab

Some of the best long-term investment stocks include companies that are in good financial standing, have a low valuation and pay consistent dividends.

Best Long-Term Investment Stocks to Buy

Investors continue to be optimistic about MDT due to its impressive international expansion. Yet, the dull macroeconomic scenario poses a concern to the company's margins.

Reasons to Retain Medtronic Stock in Your Portfolio Now

Medtronic announces new positive data for its Evolut TAVR from the Optimize PRO clinical research.

MDT Stock May Gain Following the Positive Data From Optimize PRO Study

Medtronic (NYSE: MDT) reported its Q2 fiscal 2025 results (fiscal ends in April) last week, with revenues and earnings exceeding the street estimates. The company reported revenue of $8.4 billion and adjusted earnings of $1.26 per share, compared to the consensus estimates of $8.3 billion and $1.25, respectively.

Should You Pick Medtronic Stock At $85?

Abbott Labs

Amgen

Boston Scientific

Salesforce

Gilead Sciences

Goldman Sachs

Intuit

Stryker

Tesla

Large-cap stocks are key additions to any well-rounded portfolio, but how do you find the best ones? We take a closer look here.

The Best Large-Cap Stocks to Buy

Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.

2 Very Healthy Dividend Stocks to Hold for Decades of Income

Medtronic receives an FDA nod for its InPen app, which will help launch the company's Smart MDI system.

MDT Stock Gains From FDA Approval for Its InPen App

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Medtronic (MDT) is a Strong Value Stock

Medtronic's NYSE: MDT share price is down significantly from its peak in 2021, providing investors a deep-value opportunity. The stock price is down because of the post-COVID correction and headwinds leading to sluggish growth, which are factors that will not last forever.

Medtronic: A Dividend Aristocrat Powering Up for 2025 and Beyond

Costco

Visa

3 Dividend Stocks I'll Never Sell

New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses. GALWAY, Ireland , Nov. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera™ continuous glucose monitor (CGM).

Medtronic receives FDA clearance for new InPen™ app, paving the way for its Smart MDI system launch with Simplera™ CGM

Medtronic plc reported Q2 earnings today, with revenues of $8.4bn, up 5% year-on-year, adjusted EPS of $1.26, supported by a dividend yielding 3.2%. Despite consistent mid-single-digit revenue growth and new product launches, Medtronic's share price remains flat due to unpredictable net income and modest innovation. CEO Geoff Martha highlighted strong performance and innovation in key fields such as diabetes and hypertension, but stopped short of providing specific long-term growth guidance, keeping market sentiment lukewarm.

Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday.

Gold Moves Higher; Medtronic Posts Upbeat Results

Medtronic plc (NYSE:MDT ) Q2 2025 Earnings Conference Call November 19, 2024 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Gary Corona - Interim CFO Brad Welnick - VP, IR Que Dallara - EVP and President, Diabetes Operating Unit Sean Salmon - EVP and President, Cardiovascular Portfolio Mike Marinaro - EVP and President, Medical Surgical Portfolio and Surgical Operating Unit Brett Wall - EVP and President, Neuroscience Conference Call Participants Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Pito Chickering - Deutsche Bank Anthony Petrone - Mizuho Securities Rich Newitter - Truist Securities Danielle Antalffy - UBS Joanne Wuensch - Citi Matt Miksic - Barclays Patrick Wood - Morgan Stanley Ryan Weispfenning Good morning. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations and I appreciate that you're joining us for our Fiscal '25 Second Quarter Video Earnings Webcast.

Medtronic plc (MDT) Q2 2025 Earnings Call Transcript

MDT delivers diversified growth across all its segments in the second quarter of fiscal 2025.

Medtronic Q2 Earnings and Revenues Top, Stock Down on Trimmed '25 View

Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended October 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Medtronic (MDT) Q2 Earnings: A Look at Key Metrics

Medtronic (MDT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $1.25 per share a year ago.

Medtronic (MDT) Surpasses Q2 Earnings and Revenue Estimates

Medtronic beat quarterly expectations Tuesday, but Medtronic stock dipped near a sell zone in premarket trading. The post Medtronic Beats And Raises, But Shares Flirt With A Sell Zone appeared first on Investor's Business Daily.

Medtronic Beats And Raises, But Shares Flirt With A Sell Zone

News for Medtronic Stock (MDT)